Celltaxis
PrivateLast Round
Series A
Jun 4, 2026
Total Funding Raised
$46M
Company Overview
Celltaxis is a clinical-stage biotechnology company developing pharmaceutical therapies targeting lymphatic dysfunction, including lymphedema and lipedema.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Celltaxis Comparables
Compare Celltaxis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 77% | |
| Herantis Pharma Oyj | 70% | |
| PureTech Health | 68% | |
Celltaxis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 4, 2026 | ||||
| Seed | Mar 31, 2020 |
Celltaxis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Masters Capital Management | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 31, 2020
Seed round led by Masters Capital Management.
Celltaxis Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Celltaxis's valuation, stock price, and market status.